Skip to main content
Fig. 5 | Alzheimer's Research & Therapy

Fig. 5

From: Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies

Fig. 5

Principal component analysis of biomarker data in DLB and AD patients. a, Principal component analysis in DLB patients (n = 103). Component 1 associating plasma Aβ ratio, p-tau181, and GFAP explained 19% of the variance of the biomarkers data. Component 2 associating neuroinflammation sTREM2 and YKL-40 and axonal damage NfL makers explained 40% of variance. b, Principal component analysis in AD patients (n = 76). Component 1 associating plasma Aβ ratio, p-tau181, and GFAP explained 20% of the variance of the biomarkers data. Component 2 associating neuroinflammation sTREM2 and YKL-40 and axonal damage NfL markers explained 36% of variance

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193